@article{article,

title = {Molecular diversity and evolutionary history of rabies virus strains circulating in the Balkans},

author = {L. M. McElhinney and D. A. Marston and C. M. Freuling and W. Cragg and Srđan Stankov and Dušan Lalošević and T. Müller and A. R. Fooks},

url = {https://www.pasterovzavod.rs/wp-content/uploads/2019/02/Stankov.pdf},

doi = {10.1099/vir.0.032748-0},

year  = {2011},

date = {2011-05-31},

journal = {Journal of General Virology},

number = {92},

pages = {2171–2180},

abstract = {Molecular studies of European classical rabies viruses (RABV) have revealed a number of geographically clustered lineages. To study the diversity of Balkan RABV, partial nucleoprotein (N) gene sequences were analysed from a unique panel of isolates (n5210), collected from various hosts between 1972 and 2006. All of the Balkan isolates grouped within the European/Middle East Lineage, with the majority most closely related to East European strains. A number of RABV from Bosnia & Herzegovina and Montenegro, collected between 1986 and 2006, grouped with the West European strains, believed to be responsible for the rabies epizootic that spread throughout Europe in the latter half of the 20th Century. In contrast, no Serbian RABV belonged to this sublineage. However, a distinct group of Serbian fox RABV provided further evidence for the southwards wildlife-mediated movement of rabies from Hungary, Romania and Serbia into Bulgaria. To determine the optimal region for evolutionary analysis, partial, full and concatenated N-gene and glycoprotein (G) gene sequences were compared. Whilst both the divergence times and evolutionary rates were similar irrespective of genomic region, the 95% highest probability density (HPD) limits were significantly reduced for full N-gene and concatenated NG-gene sequences compared with partial gene sequences. Bayesian coalescent analysis estimated the date of the most common recent ancestor of the Balkan RABV to be 1885 (95% HPD, 1852–1913), and skyline plots suggested an expansion of the local viral population in 1980–1990, which coincides with the observed emergence of fox rabies in the region.

},

keywords = {Rabies, rabies virus (RABV), Rabv},

pubstate = {published},

tppubtype = {article}

}

@article{article812515,

title = {Report of the First Meeting of the Middle East and Eastern Europe Rabies Expert Bureau, Istanbul, Turkey},

author = {Orhan Aylan and Aly Fahmy Mohamed El-Sayed and Firouzeh Farahtaj and Ali R. Janani and Olga Lugach and Olgha Tarkhan-Mouravi and Gaye Usluer and Rodovan Vodopija and Nenad Vranješ and Noel Tordo and Betty Dodet},

url = {https://www.pasterovzavod.rs/wp-content/uploads/2019/02/aylan2011.pdf},

doi = {10.4061/2011/812515},

year  = {2010},

date = {2010-06-08},

journal = {SAGE-Hindawi Access to Research, Advances in Preventive Medicine},

volume = {2011},

number = {812515},

pages = {4},

abstract = {Rabies is a threat in all parts of the world where animal reservoirs persists, including Eastern Europe and the Middle East. Rabies experts from seven Middle East and Eastern European countries (Croatia, Egypt, Georgia, Iran, Serbia, Turkey, and Ukraine) met for two days in Istanbul, Turkey (June 8-9, 2010), to exchange information on the epidemiological situation concerning human and animal rabies in their respective countries and to discuss strategies for rabies elimination and control. They decided to establish a regional network, the Middle East and Eastern Europe Rabies Expert Bureau (MEEREB), a regional network of experts, to increase collaboration in rabies prevention and control at the local, regional, and global levels.},

keywords = {Rabies},

pubstate = {published},

tppubtype = {article}

}

@article{article,

title = {Borrelia-like organism in heart capillaries of patient with Lyme-disease  seen by electron microscopy},

author = {Dušan Lalošević and Vesna Lalošević and Anastazija Stojšić-Milosavljević and Đurica Stojšić},

url = {https://www.pasterovzavod.rs/wp-content/uploads/2019/02/lalosevic2010.pdf},

doi = {https://doi.org/10.1016/j.ijcard.2008.12.165},

year  = {2010},

date = {2010-01-24},

journal = {International Journal of Cardiology},

volume = {145},

number = {3},

pages = {e96–e98},

abstract = {A case of a patient who developed an acute myocarditis due to Lyme disease is reported. An increased serum antibody titer to Borrelia burgdorferi suggested a diagnosis and in addition of basic clinical methods, endomyocardial biopsy performed and analyzed by transmission electron microscopy. The lumen of myocardial capillaries was founded mostly filled with detritus and fibrin precipitate, between them several bacterial fragments were identified. The electron-microscopic characteristics of the microorganisms in this specimen, revealing irregularly coiled appearance and consistent thickness of 0.2 μm, correspond to the spiral-like structure of Lyme disease borrelia. The presence of fibrin deposits on the capillary endothelium and necrosis of myocardiocytes, suggests that the cardiopathy in our patient was represent borrelia-mediated damage of the hearth microcirculation.},

keywords = {Borrelia, Clinical case, Endomyocardial biopsy, Lyme borreliosis, Ultrastructure},

pubstate = {published},

tppubtype = {article}

}

@article{article,

title = {BHK-21 cell culture rabies vaccine: Lmmunogenicity of a candidate vaccine for humans},

author = {Dušan Lalošević and Vesna Lalošević and Lj Lazarević-Ivanc and Ivana Knežević},

url = {https://www.researchgate.net/publication/51409017_BHK-21_cell_culture_rabies_vaccine_Lmmunogenicity_of_a_candidate_vaccine_for_humans},

year  = {2008},

date = {2008-01-00},

journal = {Developments in biologicals},

volume = {131},

pages = {421-9},

publisher = {https://www.researchgate.net/},

abstract = {Veterinary rabies vaccines produced in BHK-21/C13 permanent cell cultures have been used for a long period of time and have been proven as efficacious and safe. A candidate vaccine for human use (YU BHK Rabivak) was developed at the Pasteur Institute, Novi Sad, Serbia on the basis of the fixed rabies virus strain "L. Pasteur 2061/Vero 15 pas" using BHK 21/C13 as a cell substrate for vaccine production. To test the vaccine immunogenicity, a clinical trial was conducted involving 164 subjects between 18 and 60 years of age, immunized either with the YU BHK Rabivak vaccine candidate orwith a commercially available vaccine (Rabipur). Three groups of subjects were immunized with either vaccine by intramuscular administration in the deltoid region, following a pre-exposure regimen on days 0, 7 and 21, or the Essen or Zagreb post-exposure regimens. Rabies virus neutralizing antibodies (VNA) titres were determined by rapid fluorescent focus inhibition test (RFFIT) 21 and 30-45 days post vaccination. A protective titre of VNAs (>0.5 IU/ml) was found in all subjects vaccinated. Dynamics of the immune response showed that 96.4% of the subjects developed protective VNA titres after two doses, 99.3% after three doses and 100% after four and five doses of the candidate YU BHK Rabivak vaccine. There was a low reactogenicity without serious adverse events indicating a satisfactory safety profile in humans. Results obtained in this study indicate that BHK 21 cells offer the possibility of producing an efficacious and safe cell-culture rabies vaccine for humane use.},

keywords = {BHK-21/C13, Rabies},

pubstate = {published},

tppubtype = {article}

}